Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy - Cortes, Jorge E.; Kim, Dong-Wook; Nicolini, Franck E; Saikia, Tapan; Charbonnier, Aude; Apperley, Jane F.; Rathnam, Krishna; Deininger, Michael W.; De Lavallade, Hugues; Khattry, Navin; Whiteley, Andrew; Mauro, Michael J.; et al. (Blood, 2019)